Table 3. Distribution of efflux genes among clinical and non-clinical resistant enterococcus isolates.
| Antimicrobial agents | Non-clinical isolates% (N) | Clinical isolates% (N) | ||||||
|---|---|---|---|---|---|---|---|---|
| CIP (15), GEN (9), VAN (1), CHX (19), BCC (26) | CIP (38), GEN (40), VAN (18), CHX (34), BCC (16) | |||||||
| efrAB | P-value | emeA | P-value | efrAB | P-value | emeA | P-value | |
| CHX | 74 (14) | 0 | 53 (10) | 0.01 | 82 (28) | 0.01 | 68 (23) | 0.04 |
| BCC | 19 (5) | - | 15 (4) | - | 53 (8) | 0.1 | 40 (6) | - |
| CIP | 27 (7) | - | 15 (4) | - | 61 (23) | 0.01 | 53 (20) | 0.2 |
| GEN | 78 (7) | 0.01 | 56 (5) | 0.1 | 65 (26) | 0.13 | 55 (22) | 0.3 |
CIP, ciprofloxacin; GEN, gentamicin; VAN, vancomycin; CHX, chlorhexidine gluconate; BCC, benzalkonium chloride.